Traditional in vitro models, such as 2D cell cultures, lack the complexity and predictive accuracy needed for effective drug screening. 3D models, including patient-derived organoids, can offer a more predictive approach to preclinical drug development. However, the diversity of biological samples, cell types, and varying sample quality creates challenges for scientists leveraging these 3D models to generate unbiased data and uncover true biological insight.
To address these real-world challenges, this meeting brings together numerous leaders within the 3D cell culture and screening world to provide guidance on navigating processing and analysis decisions and applying some of the best strategies and technologies for a variety of user-cases. Transitioning from 2D to 3D cell culture requires robust and defined approaches including, media, matrix and cell dispensing. The preparation of relevant 3D model systems using multi-cellular subsets and matrices is key to develop the relevant models for drug discovery and limit drug attrition rates. We’ll discuss current best practices and innovative solutions to help drive your translational research.
By applying these methods and tools, we aim to help you successfully screen, analyze and drive the use of more clinically relevant and predictive models to reduce the attrition rate and accelerate drug discovery to advance human health.
